Literature DB >> 10347245

Molecular determinants of (+)-tubocurarine binding at recombinant 5-hydroxytryptamine3A receptor subunits.

A G Hope1, D Belelli, I D Mair, J J Lambert, J A Peters.   

Abstract

The 5-hydroxytryptamine type 3 (5-HT3) receptor is a transmitter-gated ion channel mediating neuronal excitation. The receptor native to neurons, or as a homopentameric assembly of 5-HT3A receptor subunits, displays a species-dependent pharmacology exemplified by a 1800-fold difference in the potency of (+)-tubocurarine [(+)-Tc] as an antagonist of the current response mediated by mouse and human receptor orthologs. Here, we attempt to identify amino acid residues involved in binding (+)-Tc by use of chimeric and mutant 5-HT3A subunits of mouse and human expressed in Xenopus laevis oocytes. Replacement of the entire extracellular N-terminal domain of the mouse 5-HT3A (m5-HT3A) subunit by that of the human ortholog and vice versa exchanged the differential potency of (+)-Tc, demonstrating the ligand binding site to be contained wholly within this region. Mutagenesis of multiple amino acid residues within a putative binding domain that exchanged nonconserved residues between mouse and human receptors shifted the apparent affinity of (+)-Tc in a reciprocal manner. The magnitude of the shift increased with the number of residues (3, 5, or 7) exchanged, with septuple mutations of m5-HT3A and human 5-HT3A subunits producing a 161-fold decrease and 53-fold increase in the apparent affinity of (+)-Tc, respectively. The effect of point mutations was generally modest, the exception being m5-HT3A D206E, which produced a 9-fold decrease in apparent affinity. We conclude that multiple amino acids within a binding loop of human and mouse 5-HT3A subunits influence the potency of (+)-Tc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347245     DOI: 10.1124/mol.55.6.1037

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  Prediction of 5-HT3 receptor agonist-binding residues using homology modeling.

Authors:  David C Reeves; Muhammed F R Sayed; Pak-Lee Chau; Kerry L Price; Sarah C R Lummis
Journal:  Biophys J       Date:  2003-04       Impact factor: 4.033

2.  Mapping spatial relationships between residues in the ligand-binding domain of the 5-HT3 receptor using a molecular ruler.

Authors:  Heather L Nyce; Spencer T Stober; Cameron F Abrams; Michael M White
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

3.  The 5-HT3B subunit affects high-potency inhibition of 5-HT3 receptors by morphine.

Authors:  Daniel T Baptista-Hon; Tarek Z Deeb; Nidaa A Othman; Douglas Sharp; Tim G Hales
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 4.  Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.

Authors:  Tina K Machu
Journal:  Pharmacol Ther       Date:  2011-02-26       Impact factor: 12.310

Review 5.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

6.  Colchicine: a novel positive allosteric modulator of the human 5-hydroxytryptamine3A receptor.

Authors:  A N de Oliveira-Pierce; R Zhang; T K Machu
Journal:  J Pharmacol Exp Ther       Date:  2009-02-02       Impact factor: 4.030

Review 7.  The 5-HT3 receptor--the relationship between structure and function.

Authors:  Nicholas M Barnes; Tim G Hales; Sarah C R Lummis; John A Peters
Journal:  Neuropharmacology       Date:  2008-08-12       Impact factor: 5.250

8.  High affinity binding of epibatidine to serotonin type 3 receptors.

Authors:  Renaldo C Drisdel; Douglas Sharp; Tricia Henderson; Tim G Hales; William N Green
Journal:  J Biol Chem       Date:  2007-08-15       Impact factor: 5.157

Review 9.  Discriminating between 5-HT₃A and 5-HT₃AB receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 10.  5-HT(3) receptors.

Authors:  Sarah C R Lummis
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.